Monthly Archives: June 2012

TB: A Faster Pace in Progress Against the Wasting Disease

By William Looney | Published: June 11, 2012
Multidrug resistant [MDR] TB is the front line in the global battle against infectious disease. It accounts for more than 5 per cent of new cases of TB, which itself takes more than 2 million lives per year – a death toll second only to HIV.  More important, multidrug resistant TB is now found in [...]
Posted in Global | Tagged , , | 1 Comment

FDA Feels Pinch of House Funding Cuts

By Guest Blogger | Published: June 8, 2012
By Amy Ritter. The House Appropriations Committee released the fiscal year 2013 Agriculture Appropriations bill, which, sets proposed spending levels for FDA as well as for other programs. The bill calls for nearly $ 2.5 billion in discretionary funding, a cut of $16.3 million, or 0.7%, below last year’s level. Total proposed funding for the FDA, [...]
Posted in Guest Blog, Regulatory | Tagged , , | Leave a comment

Drug Innovation: Alive and Well at ASCO!

By Guest Blogger | Published: June 6, 2012
By John Otrompke. This year’s annual meeting of the American Society of Clinical Oncology (ASCO), which ended on Tuesday, provided many examples of emerging therapies that offer new hope to even those patients with metastatic disease. Improved results in progression-free survival in clinical trials suggest that many forms of cancer may soon take on a more [...]
Posted in Events, Guest Blog, R&D | Tagged , , | 1 Comment

FDA User Fee Legislation Heads Toward Finish Line

By Jill Wechsler | Published: June 1, 2012
Legislation to reauthorize Food and Drug Administration user fee programs sailed through the House and Senate last month, setting the stage for leading legislators to resolve their differences and agree on a compromise measure. Much of the work will be tackled by Committee staffers who have been laboring over the legislative details for months. The [...]
Posted in Agency Insight, FDA, Regulatory | Tagged , , , | Leave a comment